Integrative medicine interventions found to significantly reduce pain, improve quality of life

 

  • New study points to sustainable effects of patient-centered care

 

Durham, NC, USA (July 22, 2013) – An integrative approach to treating chronic pain significantly reduces pain severity while improving mood and quality of life, according to a new study from the Bravewell Practice-Based Research Network (BraveNet) published last month in BioMed Central Complementary and Alternative Medicine journal. Researchers found a reduction in pain severity of more than 20 percent and a drop in pain interference of nearly 30 percent in patients after 24 weeks of integrative care. Significant improvements in mood, stress, quality of life, fatigue, sleep and well-being were also observed.

 

"Chronic pain is very difficult to treat," said lead researcher Dr. Donald Abrams, a cancer and integrative medicine specialist at the University of California San Francisco Osher Center for Integrative Medicine. "While there have been some therapeutic advances, many patients with chronic pain become resistant to conventional medical treatments or suffer adverse effects from widely used prescription medications with high addictive potential. The results from this study are particularly encouraging as chronic pain is the number one condition for which patients seek care at integrative healthcare clinics."

 

Chronic pain affects nearly 116 million American adults, with estimated costs tallying up to $635 billion annually. The prospective, observational study tracked patients‘ measures of pain, quality of life, mood, stress, sleep, fatigue, sense of control, overall well-being, and work productivity in 252 patients at nine different clinical sites.

 

In keeping with the integrative medicine philosophy of individualized, patient-centered care, no standardized pre-specified clinical intervention for chronic pain was prescribed for all study participants. Instead, practitioners at each of the network sites devised integrative treatment plans for participating chronic pain patients. All BraveNet sites include integrative physicians, acupuncturists, mindfulness instructors, and yoga instructors; some also incorporate massage therapists, manual medicine therapists, fitness/movement specialists, dietician/nutritionists, psychologists, healing touch therapists, and other energy practitioners.

 

The results of the study were consistent over the 24-week duration of the trial, suggesting the possibility of sustainable effects of the integrative interventions.

 

 

 

 

 

About BraveNet

 

BraveNet was established by The Bravewell Collaborative in 2007. The first practice-based research network in integrative medicine, BraveNet is comprised of ten leading centers in integrative medicine, with the Duke Clinical Research Center acting as the coordinating center. More information is available at https://bravenet.dcri.duke.edu

 

 

About The Bravewell Collaborative

 

Formed in 2002, The Bravewell Collaborative is a community of philanthropists in the United States dedicated to bringing about optimal health and healing for individuals and society. An operating foundation, Bravewell develops and manages strategic initiatives that support integrative approaches to healthcare. Embracing rigorous research and scientific approaches in the entirety of its work, The Bravewell Collaborative’s key initiatives include programs to educate the general public, change the way physicians are educated, develop leading clinical centers as models for change, acknowledge and support leaders in the field, and promote translational and outcomes-based research. Most recently, The Bravewell Collaborative established the first practice-based research network in integrative medicine and worked with the Institute of Medicine at the National Academies of Science to produce a National Summit on Integrative Medicine. For more information about The Bravewell Collaborative, please visit http://www.bravewell.org

 


 

BraveNet, 22.07.2013 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…